Ivonescimab Delays Lung Cancer Progression in EGFR-Mutated Disease

By News Health
3 weeks Ago

(MedPage Today) — Adding ivonescimab to chemotherapy prolonged progression-free survival (PFS) in previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC), but failed to significantly improve overall survival (OS), the phase…

Source link : https://www.medpagetoday.com/meetingcoverage/iaslc/117380

Author :

Publish date : 2025-09-09 19:22:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Surgical Consultation in the ED Needs Reform

Jenny McCarthy's Glutathione and Tylenol Claims: Medical Toxicologist Weighs In

White House, Pfizer Announce Deal for 'Most Favored Nation' Drug Pricing

Life Expectancy Gains Slow: Is 100 Years Out of Reach?

Mom's COVID Shot Aided Baby, Too, Large Review Confirmed

Proton Beam Therapy No Better Than Radiotherapy in Head and Neck Cancer